XTALPi Debuts on HKEX as First AI-Driven Drug Discovery Company; Hengrui's 'Dual-Ai' Regimen for Neoadjuvant Colorectal Cancer Published in The Lancet Oncology

1. XtalPi Holdings Limited, the First AI Drug Discovery Company, Listed on HKEX Today

On June 13, 2024, XtalPi was listed on the Hong Kong Stock Exchange, becoming the first technology company in history to go public under Rule 18C. Yesterday, XtalPi-P (02228.HK) closed at HK$5.39 in the gray market, up 2.08%, earning HK$110 per hand. Eight years ago, XtalPi gained prominence in a crystal form prediction blind test hosted by Pfizer. In the competition, this team of only 30 people not only achieved an astonishing 100% prediction success rate, surpassing many industry leaders, but also significantly reduced the time required for predictions.

2. Hengrui Pharma's "Double Ai" Combination Neoadjuvant Therapy for Colorectal Cancer Study Published in The Lancet Oncology

Hengrui Pharma's "Double Ai" Combination Neoadjuvant Therapy for Locally Advanced MSI-H/dMMR Colorectal Cancer Published in The Lancet Oncology: Study Shows 73% Complete Response Rate, Demonstrating Efficacy and Safety, Offering New Treatment Option and Potential for Organ Function Preservation.

3. Chinese pharmaceutical companies are making Singapore an important destination in the "Asian market," including Junshi Biosciences, Wuxi AppTec, and others.

Chinese pharmaceutical companies such as Junshi Biosciences, WuXi AppTec, and others have increasingly chosen Singapore as a key destination in the Asian market. Leveraging its favorable policies and market potential, these companies are expanding into Southeast Asia. Junshi Biosciences is collaborating with Chemshark Pharma to develop drugs, while WuXi AppTec has established an R&D and production base in Singapore. GenScript Biotech has also set up a regional life sciences headquarters to meet customer demands in the Asia-Pacific region.

4. China's First Medical Dietary Supplier with Clinical RCT Scientific Validation, Health Management Effectiveness Reaches Over 90%

China Faces Significant Chronic Disease Challenges, with Urgent but Unmet Medical Dietary Needs. Little Ant Doctor Group fills this gap by launching clinically validated prescription medical diets and an AI-based chronic disease management system, aiming to reduce the incidence and mortality of chronic diseases while improving family health indices. The founder and CEO, Zhang Zhenying, leverages years of experience to successfully establish the "Pumpkin Health" platform, providing precise nutritional solutions for chronic disease patients.

5. Catug Biotechnology Completes Nearly 100 Million Yuan in New Round of Financing, Accelerating the Upgrade of International Service Capabilities for the Entire Process of Nucleic Acid Drugs

On June 12, 2024, Catug Biotechnology announced the completion of a new round of financing worth nearly 100 million yuan. This round of financing was led by EF Capital and Zhiyi Investment, with follow-up investments from Yuanhe Holdings and Suzhou Industrial Park Science and Technology Innovation Fund. Established in 2021, Catug Biotechnology has been committed to the advanced therapy field from the outset, focusing on innovative nucleic acid drug CRDMO services. The funds from this round will be used to upgrade Catug Biotechnology's overseas business and full-process CRDMO service capabilities, strengthening the company's core competitiveness in the nucleic acid drug technology track.